Raymond James Trust’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.12M | Buy |
1,064
+30
| +3% | +$33.4K | 0.02% | 466 |
|
|
2024
Q2 | $1.09M | Sell |
1,034
-13
| -1% | -$12.6K | 0.03% | 450 |
|
|
2024
Q1 | $1.01M | Buy |
1,047
+89
| +9% | +$84.6K | 0.02% | 469 |
|
|
2023
Q4 | $841K | Buy |
958
+95
| +11% | +$78.2K | 0.02% | 506 |
|
|
2023
Q3 | $710K | Buy |
863
+185
| +27% | +$145K | 0.02% | 516 |
|
|
2023
Q2 | $487K | Buy |
678
+9
| +1% | +$6.94K | 0.01% | 679 |
|
|
2023
Q1 | $549K | Buy |
669
+69
| +12% | +$52K | 0.02% | 593 |
|
|
2022
Q4 | $433K | Sell |
600
-112
| -16% | -$82.6K | 0.01% | 667 |
|
|
2022
Q3 | $490K | Buy |
712
+27
| +4% | +$17K | 0.02% | 587 |
|
|
2022
Q2 | $405K | Sell |
685
-150
| -18% | -$97.5K | 0.01% | 659 |
|
|
2022
Q1 | $583K | Sell |
835
-53
| -6% | -$33.5K | 0.02% | 575 |
|
|
2021
Q4 | $561K | Buy |
888
+26
| +3% | +$16K | 0.02% | 594 |
|
|
2021
Q3 | $521K | Buy |
862
+74
| +9% | +$45.9K | 0.02% | 603 |
|
|
2021
Q2 | $440K | Sell |
788
-71
| -8% | -$36K | 0.01% | 667 |
|
|
2021
Q1 | $407K | Sell |
859
-747
| -47% | -$364K | 0.01% | 673 |
|
|
2020
Q4 | $776K | Sell |
1,606
-35
| -2% | -$18.9K | 0.03% | 405 |
|
|
2020
Q3 | $919K | Sell |
1,641
-16
| -1% | -$9.7K | 0.04% | 342 |
|
|
2020
Q2 | $1.03M | Buy |
1,657
+614
| +59% | +$349K | 0.05% | 293 |
|
|
2020
Q1 | $509K | Buy |
1,043
+245
| +31% | +$101K | 0.03% | 397 |
|
|
2019
Q4 | $300K | Buy |
798
+26
| +3% | +$8.75K | 0.01% | 687 |
|
|
2019
Q3 | $214K | Buy |
772
+58
| +8% | +$17.2K | 0.01% | 829 |
|
|
2019
Q2 | $224K | Buy |
714
+65
| +10% | +$21.6K | 0.01% | 781 |
|
|
2019
Q1 | $266K | Sell |
649
-255
| -28% | -$105K | 0.02% | 656 |
|
|
2018
Q4 | $337K | Sell |
904
-21
| -2% | -$7.69K | 0.02% | 517 |
|
|
2018
Q3 | $374K | Sell |
925
-2
| -0.2% | -$761 | 0.02% | 541 |
|
|
2018
Q2 | $320K | Buy |
927
+105
| +13% | +$32.8K | 0.02% | 585 |
|
|
2018
Q1 | $283K | Buy |
822
+43
| +6% | +$15K | 0.02% | 550 |
|
|
2017
Q4 | $293K | Sell |
779
-47
| -6% | -$19K | 0.02% | 541 |
|
|
2017
Q3 | $370K | Sell |
826
-73
| -8% | -$34.7K | 0.03% | 464 |
|
|
2017
Q2 | $441K | Buy |
899
+71
| +9% | +$31.1K | 0.03% | 401 |
|
|
2017
Q1 | $320K | Buy |
828
+70
| +9% | +$25.9K | 0.02% | 487 |
|
|
2016
Q4 | $279K | Buy |
758
+68
| +10% | +$25.9K | 0.02% | 507 |
|
|
2016
Q3 | $278K | Buy |
+690
| New | +$277K | 0.02% | 484 |
|
Other funds holding REGN
Raymond James Trust's REGN Position: Q3 2024 in Review
Raymond James Trust increased its Regeneron Pharmaceuticals (REGN) stake by 2.9% in Q3 2024, buying an estimated $33.4K and bringing the position to 1,064 shares worth $1.12M. The position accounts for 0.02% of the portfolio, ranked #466.
Raymond James Trust first reported a position in REGN in Q3 2016 and has held it in 33 quarters since. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.
- Raymond James Trust held 1,064 shares of Regeneron Pharmaceuticals worth $1.12M as of Q3 2024.
- Raymond James Trust bought 30 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $33.4K.
- Regeneron Pharmaceuticals made up 0.02% of Raymond James Trust's portfolio in Q3 2024, its #466 holding.
- Raymond James Trust first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 33 quarters since.
- 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.
Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.